|Articles|October 31, 2022
Massive Bio Onboards Over 100,000 Cancer Patients
Advertisement
Massive Bio announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022. The Massive Bio platform matches cancer patients with relevant clinical trials using AI.
Read more about the platform and its enrollment
.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
One Clinical: Working Together to Advance Trial Collaboration
2
Syneos Health Expands AI Ecosystem With Three New Platform Partnerships
3
ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma
4
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
5